10 Best Managed Healthcare Stocks To Watch For 2014

NEW YORK (MarketWatch) ��Treasury prices edged down Friday but posted a weekly advance as Ukraine worries have boosted safety plays.

The benchmark 10-year Treasury note (10_YEAR) �yield, which moves inversely to price, edged up 1 basis point to 2.655%. For the week, the yield is showing a drop of nearly 14 basis points.

The 30-year bond (30_YEAR) �yield was up nearly 1 basis point to 3.597%, while the 5-year note (5_YEAR) yield rose 1 basis point to 1.534%.

Top 5 Life Sciences Companies To Buy Right Now: Pozen Inc.(POZN)

POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and other pain-related conditions in the United States. Its products include Treximet for acute treatment of migraine attacks with or without aura in adults; and VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. The company also develops PA32540, a product candidate, which is under 2 pivotal Phase 3 trials for the secondary prevention of cardiovascular disease in patients at risk for gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and with AstraZeneca AB for the development and commercialization of proprietary fixed dose combi nations of the proton pump inhibitor esomeprazole magnesium with the NSAID naproxen. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

Advisors' Opinion:

• [By James E. Brumley]

  At first glance, POZEN Inc. (NASDAQ:POZN) doesn't look like anything more than a volatile mover and shaker, currently overbought, and due for a dip. And truth be told, POZN is overbought and due for a pullback (and will be even more so, given this morning's bullish pre-market activity). When you take a step back and look at the much-bigger-picture though, you'll find that POZEN Inc. is only at the beginning of what could be a sizeable move for investors willing to give it some time.

• [By Garrett Cook]

  Healthcare shares dropped by 0.34 percent in the US market on Wednesday. Top losers in the sector included POZEN (NASDAQ: POZN), down 7.2 percent, and Ligand Pharmaceuticals (NASDAQ: LGND), off 5.5 percent.

10 Best Managed Healthcare Stocks To Watch For 2014: SPDR DB International Government Inflation-Protected Bond ETF (WIP)

SPDR DB International Government Inflation-Protected Bond ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the DB Global Government ex-US Inflation-Linked Bond Capped Index (the Index). The Index measures the performance of the inflation-linked government bond markets of developed and emerging market countries outside of the United States. Inflation protected public obligations of the inflation-linked government bond markets of developed and emerging market countries, commonly known in the United States as treasury inflation-protected securities (TIPS), are securities issued by such governments that are designed to provide inflation protection to investors. The Fund uses a passive management strategy to track the Index. The Fund�� investment advisor is SSgA Funds Management, Inc. Advisors' Opinion:

• [By Richard Stavros]

  With respect to inflation protected bonds, though TIPS should be a part of every portfolio. However, we believe the SPDR DB International Government Inflation-Protected Bond (WIP) offers greater protection than TIPS.

10 Best Managed Healthcare Stocks To Watch For 2014: NetSpend Holdings Inc.(NTSP)

Netspend Holdings, Inc., together with its subsidiaries, provides general purpose reloadable (GPR) prepaid debit and payroll cards, and alternative financial service solutions to underbanked and other consumers in the United States. Its GPR cards offer access to FDIC-insured depository accounts with a menu of pricing and features tailored to underbanked consumers needs; and serves as access devices to an FDIC-insured depository account with a bank. The company also provides various products and services to its cardholders, such as direct deposit, interest-bearing savings accounts, bill pay functionality, card-to-card transfer capability, personal financial management tools, and online and mobile phone card account access, as well as overdraft protection through its issuing Banks, and complimentary insurance coverage services. Netspend Holdings, Inc. markets its cards through various distribution channels, including retail distributors, direct-to-consumer and online marketi ng programs, and contractual relationships with corporate employers. As of December 31, 2011, it offered approximately 2.1 million active cards through approximately 600 retail distributors at approximately 40,000 locations; and reload services through approximately 450 retailers at approximately 130,000 locations. The company was founded in 1999 and is based in Austin, Texas.

Advisors' Opinion:

• [By Jane Edmondson]

  One additional item of note: the stock has been a rumored take-out candidate since another large competitor, NetSpend (NTSP), received an offer to be acquired in February by global payment solutions provider TSYS (TSS).

10 Best Managed Healthcare Stocks To Watch For 2014: Schweitzer-Mauduit International Inc.(SWM)

Schweitzer-Mauduit International, Inc. manufactures and sells paper and reconstituted tobacco products to the tobacco industry, as well as specialized paper products for use in various applications. It operates in two segments, Paper and Reconstituted Tobacco. The Paper segment primarily produces cigarette papers, such as lower ignition propensity papers, plug wrap papers, and base tipping papers to cigarette manufacturers that use to wrap various parts of a cigarette. It also offers commercial and industrial products, including lightweight printing and writing papers, battery separator papers, drinking straw wraps, filter papers, and other specialized papers to converters and other end-users or brokers. The Reconstituted Tobacco segment produces and sells reconstituted tobacco leaf, and wrapper and binder products to cigarette and cigar manufacturers. The company sells its products directly to customers in approximately 90 countries. Schweitzer-Mauduit International, Inc. was founded in 1995 and is headquartered in Alpharetta, Georgia.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Schweitzer-Mauduit International (NYSE: SWM  ) , whose recent revenue and earnings are plotted below.

• [By Tannor Pilatzke]

  Schweitzer-Mauduit, Cigarette Paper Manufacturer (SWM) ��1995 Spin-off

  This is the big winner of the portfolio of spin-offs and logically makes the most sense. The price has increased by around 500% since 1995, not including dividends. The Company manufactures and sells paper and reconstituted tobacco products to the tobacco industry as well as specialized paper products for use in other applications. The primary products in the group include cigarette, plug wrap and tipping papers, or Cigarette Papers, used to wrap various parts of a cigarette and reconstituted tobacco leaf, or RTL, which is used as a blend with virgin tobacco in cigarettes, reconstituted tobacco wrappers and binders for cigars. These products are sold directly to the tobacco companies or their designated converters in the Americas, Europe, Asia and elsewhere. Non-tobacco products are a diverse mix of products that includes low volume, high-value engineered papers as well as commodity paper grades produced to maximize machine utilization.

10 Best Managed Healthcare Stocks To Watch For 2014: Rock-Tenn Co (RKT)

Rock-Tenn Company (RockTenn), incorporated on September 20, 1985, is a North America's integrated manufacturer of corrugated and consumer packaging. The Company operates locations in the United States, Canada, Mexico, Chile, Argentina, Puerto Rico and China. The Company operates in three segments: Corrugated Packaging, consisting of its containerboard mills and its corrugated converting operations; Consumer Packaging, consisting of its coated and uncoated paperboard mills, consumer packaging converting operations and merchandising display facilities, and Recycling, which consists of its recycled fiber brokerage and collection operations. On June 22, 2012, the Company acquired Mid South Packaging LLC. On October 28, 2011, the Company acquired four entities doing business as GMI Group.

Corrugated Packaging Segment

The Company is a producer of linerboard and corrugated medium (containerboard) measured by tons produced and a producer of graphics pre-printed linerboard in North America. It operates an integrated system, which manufactures containerboard, corrugated sheets, corrugated packaging and preprinted linerboard for sale to industrial and consumer products manufacturers and corrugated box manufacturers. It produces a range of corrugated containers designed to protect, ship, store and display products made to its customers' merchandising and distribution specifications. It also converts corrugated sheets into corrugated products ranging from one-color protective cartons to point-of-purchase packaging. Corrugated packaging is used to provide protective packaging for shipment and distribution of food, paper, health and beauty and other household, consumer, commercial and industrial products and in the case of graphically enhanced corrugated packaging for retail sale, particularly in club store locations and retail sale. It also provides structural and graphic design, engineering services, and custom and standard automated packaging machines, offering customers turn-key instal! lation, automation, line integration and packaging solutions. It feeds linerboard and corrugated medium into corrugators, which flutes the medium to specified sizes, glues the linerboard and fluted medium together and slits and cuts the resulting corrugated paperboard into sheets to customer specifications. Its container board mills and corrugated container operations are integrated with its containerboard production used internally by its corrugated container operations. During the fiscal year ended September 30, 2012 (fiscal 2012), sales of corrugated packaging products to external customers accounted for 65.7% of its net sales.

Consumer Packaging Segment

The Company operates an integrated system of coated recycled mills and a bleached paperboard mill, which produces paperboard for its folding carton operations and third parties. The Company is a manufacturer of folding cartons in North America measured by net sales. Its folding cartons are used to package food, paper, health and beauty and other household consumer, commercial and industrial products for retail sale. It also manufactures express mail envelopes for the overnight courier industry. Folding cartons protect customers��products during shipment and distribution and employ graphics to promote them at retail. It manufactures folding cartons from recycled and virgin paperboard, laminated paperboard and substrates with specialty characteristics, such as grease masking and microwaveability. It prints, coats, die-cuts and glues the cartons to customer specifications. It ships finished cartons to customers for assembling, filling and sealing. It employs a range of offset, flexographic, gravure, backside printing, and coating and finishing technologies. It supports its customers with package development, innovation and design services and package testing services.

The Company manufactures temporary and permanent point-of-purchase displays. The Company designs, manufactures and packs temporary displays for sal! e to cons! umer products companies. These displays are used as marketing tools to support new product introductions and specific product promotions in mass merchandising stores, supermarkets, convenience stores, home improvement stores and other retail locations. It also designs, manufactures and pre-assemble permanent displays for the same categories of customers. It makes temporary displays from corrugated paperboard. It provides contract packing services, such as multi-product promotional packing and product manipulation, such as multipacks and onpacks. The Company manufactures lithographic laminated packaging for sale to its customers, which require packaging with graphics and strength characteristics.

The Company operates an integrated system of specialty recycled paperboard mills, which includes its Seven Hills Paperboard LLC (Seven Hills) joint venture. Its specialty recycled paperboard mills, excluding Seven Hills, produce paperboard for its solid fiber interior packaging converting operations and third parties, and its Seven Hills joint venture manufactures gypsum paperboard liner for sale to its joint venture partner. It sells its specialty recycled paperboard to manufacturers of solid fiber interior packaging, tubes and cores, and other paperboard products. It also converts specialty paperboard into book covers and other products. Its 65% owned subsidiary, RTS, designs and manufactures solid fiber and corrugated partitions and die-cut paperboard components. It manufactures and sells its solid fiber and corrugated partitions principally to glass container manufacturers and producers of beer, food, wine, spirits, cosmetics and pharmaceuticals and to the automotive industry. During fiscal 2012, sales of consumer packaging products to external customers accounted for 27.5% of its net sales.

Recycling Segment

The Company�� recycled fiber brokerage and collection operations provide a strategic advantage to its mills. Its recycling operations procure recovered paper (or! recycled! fiber) for its paper mills, as well as for third parties from factories, warehouses, commercial printers, office complexes, grocery and retail stores, document storage facilities, paper converters and other wastepaper collectors. It handles a range of grades of recovered paper, including old corrugated containers, office paper, box clippings, newspaper and print shop scraps. It operates recycling facilities, which collects, sorts, grades and bales recovered paper and after sorting and baling, it transfer recovered paper to its paperboard mills for processing, or sell it to the United States manufacturers of paperboard, as well as manufacturers of tissue, newsprint, roofing products and insulation and to export markets. It also collects aluminum and plastics for resale to manufacturers of these products. Its waste reduction services extract additional recyclables from the waste stream by working with customers. In addition, it operates a nationwide fiber marketing and brokerage system, which serves regional and national accounts, as well as its recycled paperboard and containerboard mills and sells scrap materials from its converting businesses and mills. Brokerage contracts provide bulk purchasing. Its recycling facilities are located close to its recycled paperboard and containerboard mills, ensuring availability of supply with reduced shipping costs. During fiscal 2012, sales to external customers accounted for 6.8% of its net sales.

Advisors' Opinion:

• [By BLOGS.BARRONS.COM]

  Ng writes that MLP creation could produce 30% to 50% gains in three stocks: International Paper (IP), Packaging Corp. of America (PKG) and Rock-Tenn Co. (RKT).� International Paper shares are up 2% this morning to 47.67; Packaging Corp. is 2% higher at 63.69 and Rock-Tenn is up 1.5% to 47. He continues:

10 Best Managed Healthcare Stocks To Watch For 2014: Dynavax Technologies Corporation(DVAX)

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a Phase 1b clinical trial vaccine for influenza prevention; SD-101, a Phase Ib clinical trial hepatitis C therapy; DV-601, a Phase Ib clinical trial hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a Phase 1 trial autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize DV1179 and other endosomal toll-like receptor inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis; and develop a TLR8 inhibitor for the treatment of multiple autoimmune and i nflammatory diseases, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was founded in 1996 and is based in Berkeley, California.

Advisors' Opinion:

• [By Holly LaFon]

  Steven Cohen, George Soros and John Paulson are three of the most formidable investors alive today. All three of them added to one of their major holdings so far in 2012. Steven Cohen of SAC Capital Advisors added Dynavax Tech Cp (DVAX), George Soros of Soros Fund Management LLC added Acacia Research (ACTG) and John Paulson of Paulson & Co. added Novagold Resources (NG).

10 Best Managed Healthcare Stocks To Watch For 2014: Juno Therapeutics Inc (JUNO)

Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.

To provide treatment, the Company harvests blood cells from a cancer patient, separate the appropriate T cells, activate the cells, insert the gene sequence for the CAR or TCR construct into the cells��Deoxyribonucleic Acid (DNA), and grow these modified T cells to the desired dose level. The modified T cells can then be infused into the patient or frozen and stored for later infusion. Once infused, the T cells are designed to multiply, through a process known as cell expansion, when they encounter the targeted proteins and to kill the targeted cancer cells.

CD19-Directed Product Candidates

The Company�� product candidates, such as JCAR015, JCAR017, and JCAR014, which use CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. The Company has rights to commercialize each of these product candidates across the world. The Company�� JCAR015 is an advanced development product candidate, and it has demonstrated clinically meaningful complete remission rates in adult patients with r/r ALL. JCAR015 uses the CD28 costimulatory domain and CD3 enriched peripheral blood mononuclear cells (PBMC), which requires fewer process steps for! manufacture than its defined cell composition product candidates. JCAR015 is being tested in a Phase I open label clinical trial of patients with r/r ALL for the treatment of refractory chronic lymphocytic leukemia.

JCAR017 also targets CD19, but differs from JCAR015 in several important respects. JCAR017 uses the 4-1BB costimulatory domain and a defined cell composition of CD4+ T cells and CD8+ T cells. JCAR017 is in development for pediatric patients with r/r ALL. JCAR017 is being evaluated in a Phase I/II clinical trial in pediatric r/r ALL.

JCAR014 also targets CD19. JCAR014 uses the 4-1BB costimulatory domain and is composed of CD8+ central memory T cells and CD4+ T cells in a defined ratio. JCAR014 is being evaluated in a Phase I/II trial as a treatment for a number of B cell malignancies in patients relapsed or refractory to standard therapies.

Additional Product Candidates

The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers not targeted by CD19-directed products, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung, and pancreatic cancers, as well as B cell malignancies that do not express CD19. The Company�� CD22 is a cell surface protein widely expressed on B lymphocytes. It is expressed by B cell malignancies, including non-Hodgkin�� lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The Company�� L1CAM, also known as CD171, is a cell-surface adhesion molecule that plays an important role in the development of a normal nervous system. It is overexpressed in neuroblastoma, and there is increasing evidence of aberrant expression in a variety of solid organ tumors, including glioblastoma and lung, pancreatic, and ovarian cancers.

The Company�� MUC-16 is a protein overexpressed in the ovarian cancers, but not on the surface of normal ovary cells. CA-125 is a protein found in the ! blood of ! ovarian cancer patients that results from the cleavage of MUC-16. CA-125 levels in the blood are a common test for ovarian cancer progression because they correlate with cancer progression. Its MUC-16/IL-12 product candidate uses its armored CAR technology. IL-12 is a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity.

The Company�� ROR-1 is a protein expressed in the formation of embryos, but in normal adult cells its surface expression is predominantly found at low levels on adipocytes, or fat cells, and briefly on precursors to B cells, or pre-B cells, during normal B cell maturation. ROR-1 is overexpressed on a variety of cancers including a subset of non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, and prostate cancer. It is expressed on B cell chronic lymphocytic leukemia and mantle cell lymphoma. The Company�� high-affinity TCR T cell product candidate targets WT-1, an intracellular protein that is overexpressed in a number of cancers, including adult myeloid leukemia, or AML, and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.

Advisors' Opinion:

• [By John Udovich]

  Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.